Bruton's tyrosine kinase inhibitor - Shenzhen TargetRx
Alternative Names: BTK-Inhibitor-Shenzhen TargetRxLatest Information Update: 26 Apr 2023
At a glance
- Originator Shenzhen TargetRx
- Class Antineoplastics; Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Immunological disorders; Lymphoma
Most Recent Events
- 05 Apr 2023 Bruton's tyrosine kinase inhibitor - Shenzhen TargetRx is available for licensing as of 05 Apr 2023. https://www.tjrbiosciences.com/en/index.php?m=content&c=index&a=lists&catid=50
- 05 Apr 2023 Preclinical trials in Immunological disorders in China (unspecified route) (Shenzhen TargetRx pipeline, April 2023)
- 05 Apr 2023 Preclinical trials in Lymphoma in China (unspecified route) (Shenzhen TargetRx pipeline, April 2023)